Advances and considerations in AD tau-targeted immunotherapy
The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towar...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996119303821 |
| _version_ | 1818827602555568128 |
|---|---|
| author | Alice Bittar Nemil Bhatt Rakez Kayed |
| author_facet | Alice Bittar Nemil Bhatt Rakez Kayed |
| author_sort | Alice Bittar |
| collection | DOAJ |
| description | The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towards the required role of tau in AD etiology. Importantly, a large number of studies investigate and characterize the plethora of pathological forms of tau protein involved in disease onset and propagation. Immunotherapy is one of the most clinical approaches anticipated to make a difference in the field of AD therapeutics. Tau –targeted immunotherapy is the new direction after the failure of amyloid beta (Aß)-targeted immunotherapy and the growing number of studies that highlight the Aß-independent disease process. It is now well established that immunotherapy alone will most likely be insufficient as a monotherapy. Therefore, this review discusses updates on tau-targeted immunotherapy studies, AD-relevant tau species, updates on promising biomarkers and a prospect on combination therapies to surround the disease propagation in an efficient and timely manner. |
| first_indexed | 2024-12-19T00:46:10Z |
| format | Article |
| id | doaj.art-14de4fd35ac84c58a8cc989888c3172a |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-19T00:46:10Z |
| publishDate | 2020-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-14de4fd35ac84c58a8cc989888c3172a2022-12-21T20:44:15ZengElsevierNeurobiology of Disease1095-953X2020-02-01134Advances and considerations in AD tau-targeted immunotherapyAlice Bittar0Nemil Bhatt1Rakez Kayed2Department of Neurology, The Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, United States of AmericaDepartment of Neuroscience, Cell Biology and Anatomy, Graduate School of Biomedical Sciences, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, United States of AmericaDepartment of Neurology, The Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, United States of America; Corresponding author at: University of Texas Medical Branch, 301 University Blvd, route 0539, Medical Research Bldg. Room 10.138C, Galveston, TX 77555-1045, United States of America.The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towards the required role of tau in AD etiology. Importantly, a large number of studies investigate and characterize the plethora of pathological forms of tau protein involved in disease onset and propagation. Immunotherapy is one of the most clinical approaches anticipated to make a difference in the field of AD therapeutics. Tau –targeted immunotherapy is the new direction after the failure of amyloid beta (Aß)-targeted immunotherapy and the growing number of studies that highlight the Aß-independent disease process. It is now well established that immunotherapy alone will most likely be insufficient as a monotherapy. Therefore, this review discusses updates on tau-targeted immunotherapy studies, AD-relevant tau species, updates on promising biomarkers and a prospect on combination therapies to surround the disease propagation in an efficient and timely manner.http://www.sciencedirect.com/science/article/pii/S0969996119303821Tau-targeted immunotherapyTauAmyloid Beta immunotherapyAlzheimer's diseaseBiomarkersextracellular tau |
| spellingShingle | Alice Bittar Nemil Bhatt Rakez Kayed Advances and considerations in AD tau-targeted immunotherapy Neurobiology of Disease Tau-targeted immunotherapy Tau Amyloid Beta immunotherapy Alzheimer's disease Biomarkers extracellular tau |
| title | Advances and considerations in AD tau-targeted immunotherapy |
| title_full | Advances and considerations in AD tau-targeted immunotherapy |
| title_fullStr | Advances and considerations in AD tau-targeted immunotherapy |
| title_full_unstemmed | Advances and considerations in AD tau-targeted immunotherapy |
| title_short | Advances and considerations in AD tau-targeted immunotherapy |
| title_sort | advances and considerations in ad tau targeted immunotherapy |
| topic | Tau-targeted immunotherapy Tau Amyloid Beta immunotherapy Alzheimer's disease Biomarkers extracellular tau |
| url | http://www.sciencedirect.com/science/article/pii/S0969996119303821 |
| work_keys_str_mv | AT alicebittar advancesandconsiderationsinadtautargetedimmunotherapy AT nemilbhatt advancesandconsiderationsinadtautargetedimmunotherapy AT rakezkayed advancesandconsiderationsinadtautargetedimmunotherapy |